Chapter title |
The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis
|
---|---|
Chapter number | 10 |
Book title |
Cancer Drug Resistance
|
Published in |
Methods in molecular biology, January 2016
|
DOI | 10.1007/978-1-4939-3347-1_10 |
Pubmed ID | |
Book ISBNs |
978-1-4939-3345-7, 978-1-4939-3347-1
|
Authors |
Garajová, Ingrid, Le Large, Tessa Y S, Giovannetti, Elisa, Kazemier, Geert, Biasco, Guido, Peters, Godefridus J, Ingrid Garajová, Tessa Y. S. Le Large, Elisa Giovannetti, Geert Kazemier, Guido Biasco, Godefridus J. Peters |
Editors |
Jose Rueff, António Sebastião Rodrigues |
Abstract |
Pancreatic ductal adenocarcinoma (PDAC) is a common cause of cancer death and has the worst prognosis of any major malignancy, with less than 5 % of patients alive 5-years after diagnosis. The therapeutic options for metastatic PDAC have changed in the past few years from single agent gemcitabine treatment to combination regimens. Nowadays, FOLFIRINOX or gemcitabine with nab-paclitaxel are new standard combinations in frontline metastatic setting in PDAC patients with good performance status. MicroRNAs (miRNA) are small, noncoding RNA molecules affecting important cellular processes such as inhibition of apoptosis, cell proliferation, epithelial-to-mesenchymal transition (EMT), metastases, and resistance to common cytotoxic and anti-signaling therapy in PDAC. A functional association between miRNAs and chemoresistance has been described for several common therapies. Therefore, in this review, we summarize the current knowledge on the role of miRNAs in the resistance to current anticancer treatment used for patients affected by metastatic PDAC. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 20% |
Student > Master | 3 | 15% |
Student > Bachelor | 3 | 15% |
Researcher | 3 | 15% |
Other | 2 | 10% |
Other | 5 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 40% |
Biochemistry, Genetics and Molecular Biology | 3 | 15% |
Unspecified | 1 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Nursing and Health Professions | 1 | 5% |
Other | 1 | 5% |
Unknown | 5 | 25% |